Seer (SEER) Total Non-Current Liabilities (2020 - 2026)
Seer (SEER) recorded quarterly Total Non-Current Liabilities of $30.6 million in Q1 2026, down 16.7% quarter-over-quarter from $36.8 million in Q4 2025, and down 15.45% on a YoY basis from $36.2 million in Q1 2025.
Seer (SEER) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Seer's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $30.6 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 15.45% year-over-year to $30.6 million; the TTM figure through Mar 2026 stood at $30.6 million (down 15.45% YoY), while the FY2025 annual figure was $36.8 million, down 5.67% from the prior year.
- Total Non-Current Liabilities was $30.6 million for Q1 2026 at Seer, down from $36.8 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $43.9 million in Q2 2022 to a low of $30.6 million in Q1 2026.
- Historically, Total Non-Current Liabilities has averaged $38.8 million across 5 years, with a median of $39.0 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities soared 334.12% in 2022, then slipped 18.37% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $40.6 million in 2022, then dropped by 3.52% to $39.2 million in 2023, then slipped by 0.53% to $39.0 million in 2024, then declined by 5.67% to $36.8 million in 2025, then fell by 16.7% to $30.6 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $30.6 million (Q1 2026), $36.8 million (Q4 2025), and $36.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 64.76 Mn |
| 10 | Seer | 99.67 Mn | 99.67 Mn | 982,000.00 | 30.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.63 Mn |
| Dec 31, 2025 | 36.77 Mn |
| Sep 30, 2025 | 36.78 Mn |
| Jun 30, 2025 | 34.18 Mn |
| Mar 31, 2025 | 36.22 Mn |
| Dec 31, 2024 | 38.98 Mn |
| Sep 30, 2024 | 38.63 Mn |
| Jun 30, 2024 | 41.87 Mn |
| Mar 31, 2024 | 38.23 Mn |
| Dec 31, 2023 | 39.19 Mn |
| Sep 30, 2023 | 39.02 Mn |
| Jun 30, 2023 | 42.90 Mn |
| Mar 31, 2023 | 39.44 Mn |
| Dec 31, 2022 | 40.62 Mn |
| Sep 30, 2022 | 42.13 Mn |
| Jun 30, 2022 | 43.93 Mn |
| Mar 31, 2022 | 40.29 Mn |
| Dec 31, 2021 | 35.88 Mn |
| Sep 30, 2021 | 12.24 Mn |
| Jun 30, 2021 | 10.60 Mn |